Synonyms: LCB10-0200
Compound class:
Synthetic organic
Comment: GT-1 (LCB10-0200) is a novel antibacterial compound with activity against Gram-negative bacteria [5]. Its struture, in which a siderophore (dihydroxypyridone) is conjugated to a modified aminothiazoylglycyl cephalosporin, was designed to exploit siderophore-dependent pathways for the uptake of iron across the outer membrane of Gram-negative bacteria [5-6].
|
|
No information available. |
Summary of Clinical Use ![]() |
A phase 1 study (ACTRN12618001980224) was registered in Australia in 2018 to evaluate the safety, tolerability, and pharmacokinetics of GT-1 in healthy participants but was terminated due to unspecified safety concerns. Further clinical development of GT-1, by LegoChem Biosciences (Republic of Korea) and Geom Therapeutics (USA), may have been discontinued [1]. |